LivaNova is a two-franchise medical-device company whose cardiopulmonary and epilepsy businesses are compounding faster than the market prices, while management spends the cash those franchises throw off to buy a late-stage position in obstructive sleep apnea.
The most important recent development is the second-quarter print and the second consecutive guidance raise that accompanied it. Cardiopulmonary and neuromodulation both grew at a high-single-digit constant-currency rate, and management lifted the full-year constant-currency revenue band by a full percentage point while also lifting the adjusted earnings range. The mechanism is not a one-off mix windfall. Essenz heart-lung machine placements continue to pull oxygenators and tubing behind them, and a January Medicare outpatient payment increase for vagus-nerve stimulation implants is beginning to loosen a reimbursement knot that had kept epilepsy procedure volumes below the installed clinical need. That combination is why the core is funding the next chapter rather than merely defending the last one.
The tension is that reported earnings and cash are telling different stories, and the balance sheet still carries the SNIA environmental overhang from the Italian Supreme Court ruling last year. Adjusted operating income expanded even as GAAP operating income slipped, because legal, share-based, and acquisition-related items remain large, and a discrete Italian tax benefit on the deductibility of the SNIA liability flattered GAAP earnings per share. Management also cut the adjusted free-cash-flow range to fund oxygenator capacity, innovation, and systems work. The bear case is that the core is being harvested to pay for a sleep-apnea launch that remains a 2027 limited-release event, while a mid-hundreds-of-millions environmental claim sits as a current liability.
What resolves the debate is whether oxygenator output actually rises after the Thermo Fisher supply agreement and whether aura6000, the newly approved hypoglossal-nerve stimulator, converts its regulatory clearance into paid implants without wrecking the guided adjusted operating-margin band. The equity at a recent $78 close and a market value near $4 billion is already paying a mid-teens multiple on this year's raised adjusted earnings guide. That multiple is cheap only if the core keeps compounding and the sleep-apnea option does not become a multi-year cash sink.